These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21984797)

  • 1. Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT.
    Fox JJ; Autran-Blanc E; Morris MJ; Gavane S; Nehmeh S; Van Nuffel A; Gönen M; Schöder H; Humm JL; Scher HI; Larson SM
    J Nucl Med; 2011 Nov; 52(11):1727-32. PubMed ID: 21984797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer.
    Larson SM; Morris M; Gunther I; Beattie B; Humm JL; Akhurst TA; Finn RD; Erdi Y; Pentlow K; Dyke J; Squire O; Bornmann W; McCarthy T; Welch M; Scher H
    J Nucl Med; 2004 Mar; 45(3):366-73. PubMed ID: 15001675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival.
    Vargas HA; Wassberg C; Fox JJ; Wibmer A; Goldman DA; Kuk D; Gonen M; Larson SM; Morris MJ; Scher HI; Hricak H
    Radiology; 2014 Apr; 271(1):220-9. PubMed ID: 24475817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer.
    Jadvar H; Desai B; Ji L; Conti PS; Dorff TB; Groshen SG; Pinski JK; Quinn DI
    J Nucl Med; 2013 Aug; 54(8):1195-201. PubMed ID: 23785174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reproducibility and Repeatability of Semiquantitative
    Vargas HA; Kramer GM; Scott AM; Weickhardt A; Meier AA; Parada N; Beattie BJ; Humm JL; Staton KD; Zanzonico PB; Lyashchenko SK; Lewis JS; Yaqub M; Sosa RE; van den Eertwegh AJ; Davis ID; Ackermann U; Pathmaraj K; Schuit RC; Windhorst AD; Chua S; Weber WA; Larson SM; Scher HI; Lammertsma AA; Hoekstra OS; Morris MJ
    J Nucl Med; 2018 Oct; 59(10):1516-1523. PubMed ID: 29626121
    [No Abstract]   [Full Text] [Related]  

  • 6. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ferret thoracic anatomy by 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) positron emission tomography/computed tomography (18F-FDG PET/CT) imaging.
    Wu A; Zheng H; Kraenzle J; Biller A; Vanover CD; Proctor M; Sherwood L; Steffen M; Ng C; Mollura DJ; Jonsson CB
    ILAR J; 2012; 53(1):E9-21. PubMed ID: 23382267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interobserver variability among measurements of the maximum and mean standardized uptake values on (18)F-FDG PET/CT and measurements of tumor size on diagnostic CT in patients with pulmonary tumors.
    Huang YE; Chen CF; Huang YJ; Konda SD; Appelbaum DE; Pu Y
    Acta Radiol; 2010 Sep; 51(7):782-8. PubMed ID: 20707663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
    Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
    J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does focal incidental 18F-FDG PET/CT uptake in the prostate have significance?
    Brown AM; Lindenberg ML; Sankineni S; Shih JH; Johnson LM; Pruthy S; Kurdziel KA; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
    Abdom Imaging; 2015 Oct; 40(8):3222-9. PubMed ID: 26239399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer.
    Fox JJ; Gavane SC; Blanc-Autran E; Nehmeh S; Gönen M; Beattie B; Vargas HA; Schöder H; Humm JL; Fine SW; Lewis JS; Solomon SB; Osborne JR; Veach D; Sawyers CL; Weber WA; Scher HI; Morris MJ; Larson SM
    JAMA Oncol; 2018 Feb; 4(2):217-224. PubMed ID: 29121144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.
    Zerizer I; Al-Nahhas A; Towey D; Tait P; Ariff B; Wasan H; Hatice G; Habib N; Barwick T
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1391-9. PubMed ID: 22644713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
    Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron tomographic assessment of androgen receptors in prostatic carcinoma.
    Dehdashti F; Picus J; Michalski JM; Dence CS; Siegel BA; Katzenellenbogen JA; Welch MJ
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):344-50. PubMed ID: 15726353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
    Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
    J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of SUV(max) obtained by 18F-FDG PET/CT in patients with a solitary pancreatic lesion: predicting malignant potential and proliferation.
    Hu SL; Yang ZY; Zhou ZR; Yu XJ; Ping B; Zhang YJ
    Nucl Med Commun; 2013 Jun; 34(6):533-9. PubMed ID: 23503000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.